Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Intensity Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
INTS
Nasdaq
8731
https://www.intensitytherapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Intensity Therapeutics Inc
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
- Apr 2nd, 2024 12:01 pm
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
- Mar 26th, 2024 12:01 pm
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
- Mar 14th, 2024 8:09 pm
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
- Mar 14th, 2024 12:00 pm
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
- Feb 21st, 2024 1:01 pm
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
- Jan 3rd, 2024 1:01 pm
Intensity Therapeutics (NASDAQ:INTS) Is In A Good Position To Deliver On Growth Plans
- Dec 29th, 2023 10:39 am
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
- Dec 12th, 2023 1:01 pm
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS
- Dec 8th, 2023 1:30 pm
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
- Dec 1st, 2023 1:01 pm
Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
- Nov 13th, 2023 1:01 pm
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023
- Nov 2nd, 2023 11:01 am
Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma
- Sep 7th, 2023 12:01 pm
Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 5th, 2023 12:01 pm
Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
- Aug 14th, 2023 11:01 am
Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
- Aug 7th, 2023 11:01 am
Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update
- Jul 31st, 2023 8:05 pm
Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds
- Jul 10th, 2023 12:00 pm
Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds
- Jul 5th, 2023 8:15 pm
Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds
- Jun 30th, 2023 12:00 am
Scroll